NCT07072234View on ClinicalTrials.gov

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 25, 2025

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2030

Conditions
Clear Cell CarcinomaPhase 1Growth Factor
Interventions
DRUG

Lymphodepleting chemotherapy

Given by IV

DRUG

Dexamethasone

Given PO

DRUG

Fludarabine

Given by IV

DRUG

Cyclophosphamate

Given by IV

DRUG

TGFBR-2 KO CD70 CAR NK

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER